论文部分内容阅读
目的:观察脑心通胶囊联合硝酸异山梨酯片治疗冠心病伴血脂紊乱的临床疗效和不良反应。方法:将冠心病伴血脂紊乱126例随机分为观察组64例和对照组62例。两组均采取生活方式干预及冠心病的二级预防。对照组采用硝酸异山梨酯片治疗,每次20 mg,每天2次;观察组在对照组治疗的基础上加服脑心通胶囊,每次3粒,每天3次。两组疗程均为8周,比较两组治疗后临床症状、心电图及血脂改善情况。结果:治疗后,观察组临床症状改善60例,占93.7%;对照组50例,占80.6%,两组比较差异显著(P<0.05);两组心电图改善差异显著(P<0.05)。观察组胆固醇、三酰甘油、低密度脂蛋白、高密度脂蛋白改善情况显著优于对照组(P<0.05,P<0.01),两组均未发现严重不良反应。结论:脑心通胶囊联合硝酸异山梨酯片治疗冠心病伴血脂紊乱疗效确切,且安全。
Objective: To observe the clinical efficacy and adverse reactions of Naoxintong capsule and isosorbide dinitrate tablets in treating coronary heart disease with dyslipidemia. Methods: 126 cases of coronary heart disease with dyslipidemia were randomly divided into observation group (64 cases) and control group (62 cases). Both groups adopted life-style intervention and secondary prevention of coronary heart disease. The control group was treated with isosorbide dinitrate tablets, each 20 mg twice daily; the observation group was given Naoxintong capsules three times a day on the basis of the control group. The two groups of treatment were 8 weeks, comparing the two groups after treatment, clinical symptoms, ECG and blood lipids improved. Results: After treatment, the clinical symptoms of the observation group improved 60 cases (93.7%); the control group (50 cases) accounted for 80.6%. There was significant difference between the two groups (P <0.05). The improvement of cholesterol, triglyceride, low density lipoprotein and high density lipoprotein in the observation group was significantly better than that of the control group (P <0.05, P <0.01). No serious adverse reactions were found in both groups. Conclusion: Naoxintong capsule combined with isosorbide dinitrate tablets in treating coronary heart disease with dyslipidemia is effective and safe.